Vertex CEO Unfazed By Hepatitis-C Drug Matchup Against Merck

Vertex Pharmaceuticals Inc. (VRTX) Chief Executive Matthew Emmens is ready to go toe-to-toe with one of the world's biggest pharmaceutical companies, Merck & Co. (MRK). Cambridge, Mass., based Vertex has filed for Food and Drug Administration approval of telaprevir, which has shown a sharp increase in cure rates of hepatitis C in multiple studies when added to current treatments. Merck also has shown success with its similar drug, boceprevir, and has filed for approval with expedited review granted in both the U.S. and Europe

No comments:

Post a Comment

Superhit News

News Archive